Results with PCSK9 inhibitor in ODYSSEY OUTCOMES above expectations, mortality benefit included

Media formats available:

Preventive PCI versus only optimal medical therapy for vulnerable plaques
Preventive PCI versus only optimal medical therapy for vulnerable plaques
ACC.24
Preventive PCI versus only optimal medical therapy for vulnerable plaques
- Marc Bonaca, MD
Promising results for APOC3 ASO in familial chylomicronemia syndrome
Promising results for APOC3 ASO in familial chylomicronemia syndrome
ACC.24
Promising results for APOC3 ASO in familial chylomicronemia syndrome
- Erik Stroes, MD, PhD
APOC3 ASO significantly lowers triglycerides in patients with hypertriglyceridemia and high CV risk
APOC3 ASO significantly lowers triglycerides in patients with hypertriglyceridemia and high CV risk
ACC.24
APOC3 ASO significantly lowers triglycerides in patients with hypertriglyceridemia and high CV risk
- Brian Bergmark, MD
No improvements in CV outcomes at 90 days with human ApoA-1 infusions post-MI
No improvements in CV outcomes at 90 days with human ApoA-1 infusions post-MI
ACC.24
No improvements in CV outcomes at 90 days with human ApoA-1 infusions post-MI
- Michael Gibson, MD

PACE-CME